Biotest Obtains Approval for Prufibry® in Germany

Biotest AG, a member of the Grifols Group, announced the approval of its new human fibrinogen product Prufibry® in Germany by the Paul-Ehrlich-Institut. This therapy targets patients with congenital and acquired fibrinogen deficiency, offering improved management of bleeding in surgical and trauma scenarios. Clinical trials showed its efficacy and safety in restoring fibrinogen levels and controlling bleeding.

Manufactured at the Biotest Next Level facility in Dreieich, Prufibry® represents an important addition to Biotest's intensive care offerings. The product is specifically designed for treating congenital hypo- or afibrinogenemia and providing complementary therapy for uncontrolled hemorrhage due to surgery or trauma. The launch is anticipated by the end of 2025, with plans for further expansion into other markets.